De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Coherus BioSciences Toekomstige groei

Future criteriumcontroles 5/6

Coherus BioSciences zal naar verwachting groeien in winst en omzet met respectievelijk 55.4% en 13.2% per jaar. De winst per aandeel zal naar verwachting groeien met 46.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 37.5% zijn.

Belangrijke informatie

55.4%

Groei van de winst

46.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.7%
Inkomstengroei	13.2%
Toekomstig rendement op eigen vermogen	37.5%
Dekking van analisten	Good
Laatst bijgewerkt	07 Oct 2024

Recente toekomstige groei-updates

Recent updates

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15

Coherus: Will Its Chinese Gambit Fail?

May 27

Winst- en omzetgroeiprognoses

NasdaqGM:CHRS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	373	-10	-88	-102	8
12/31/2025	311	-45	-116	-132	8
12/31/2024	264	2	287	268	6
6/30/2024	308	-29	-56	-54	N/A
3/31/2024	302	-59	-154	-153	N/A
12/31/2023	257	-238	-176	-175	N/A
9/30/2023	211	-217	-229	-262	N/A
6/30/2023	182	-264	-213	-245	N/A
3/31/2023	183	-271	-225	-256	N/A
12/31/2022	211	-292	-246	-241	N/A
9/30/2022	239	-279	-231	-193	N/A
6/30/2022	276	-230	-180	-143	N/A
3/31/2022	304	-210	-121	-93	N/A
12/31/2021	327	-287	-39	-37	N/A
9/30/2021	364	-232	-90	48	N/A
6/30/2021	395	-165	-60	82	N/A
3/31/2021	443	-76	-16	142	N/A
12/31/2020	476	132	139	154	N/A
9/30/2020	489	162	113	139	N/A
6/30/2020	487	181	125	146	N/A
3/31/2020	435	145	84	99	N/A
12/31/2019	356	90	15	28	N/A
9/30/2019	232	-12	-38	-37	N/A
6/30/2019	121	-118	-136	-134	N/A
3/31/2019	37	-185	-184	-183	N/A
12/31/2018	N/A	-209	-160	-159	N/A
9/30/2018	N/A	-196	-143	-142	N/A
6/30/2018	N/A	-196	-143	-141	N/A
3/31/2018	1	-208	N/A	-161	N/A
12/31/2017	2	-238	N/A	-200	N/A
9/30/2017	2	-265	N/A	-257	N/A
6/30/2017	165	-122	N/A	-278	N/A
3/31/2017	178	-137	N/A	-250	N/A
12/31/2016	190	-127	N/A	-253	N/A
9/30/2016	199	-104	N/A	-160	N/A
6/30/2016	44	-259	N/A	-158	N/A
3/31/2016	37	-248	N/A	-151	N/A
12/31/2015	30	-223	N/A	-108	N/A
9/30/2015	26	-200	N/A	-147	N/A
6/30/2015	35	-137	N/A	-92	N/A
3/31/2015	33	-103	N/A	-72	N/A
12/31/2014	31	-87	N/A	-24	N/A
9/30/2014	26	-73	N/A	14	N/A
6/30/2014	10	-86	N/A	41	N/A
3/31/2014	6	-70	N/A	37	N/A
12/31/2013	3	-54	N/A	15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat CHRS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).

Winst versus markt: Er wordt verwacht dat CHRS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat CHRS binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van CHRS ( 13.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van CHRS ( 13.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CHRS zal naar verwachting over 3 jaar hoog zijn ( 37.5 %)

Coherus BioSciences Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 12%

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Recent updates

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022